Lipodystrophy Market Size in the 7MM is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Lipodystrophy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the indication Lipodystrophy, historical and forecasted epidemiology as well as the Lipodystrophy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Lipodystrophy Market with DelveInsight's In-Depth Report @ Lipodystrophy Market Size [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Lipodystrophy Market Report

* In November 2024:- Amryt Pharma- An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy. This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy.
* According to DelveInsight's estimates for 2023, there were approximately 3,077 prevalent cases of rare disease lipodystrophy across the 7MM, with the United States accounting for 35% of these cases.
* In 2023, the EU4 countries and the UK together accounted for approximately 60% of the total lipodystrophy cases.
* In 2023, approximately 30% of lipodystrophy cases in the United States were classified as congenital generalized lipodystrophy. This condition involves near-total loss of body fat, resulting in prominent muscles, severe insulin resistance, early-onset diabetes, hypertriglyceridemia, and non-alcoholic fatty liver disease (NAFLD).
* In 2023, 93% of diagnosed lipodystrophy cases were partial lipodystrophy, predominantly affecting females. This is largely because familial partial lipodystrophy (FPL), a common type, is linked to genetic mutations in the LMNA or PPARG genes, which are more prevalent in women.
* The leading Lipodystrophy Companies such as Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim , and others.
* Promising Lipodystrophy Therapies such as Metreleptin, Mibavademab, Baricitinib , and others.

Stay ahead in the Lipodystrophy Therapeutics Market with DelveInsight's Strategic Report @ Lipodystrophy Market Outlook [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Lipodystrophy Epidemiology

* Total cases of Lipodystrophy
* Lipodystrophy Subtype-specific Cases
* Lipodystrophy Gender-specific Cases

Download the report to understand which factors are driving Lipodystrophy epidemiology trends @ Lipodystrophy Prevalence [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Lipodystrophy Marketed Drugs

* MYALEPT (metreleptin): Amryt Pharma

Metreleptin mimics the physiological effects of leptin by binding to and activating the human leptin receptor, which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway. Only the metabolic effects of metreleptin have been studied. No effects on the distribution of subcutaneous fat are expected.

The US Food and Drug Administration (FDA) approved MYALEPT (metreleptin) in 2014, Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients: with confirmed congenital generalized lipodystrophy or acquired generalized lipodystrophy in adults and children 2 years of age and above.

* EGRIFTA/EGRIFTA SV (tesamorelin): Thera Technologies

EGRIFTA/EGRIFTA SV is a growth hormone-releasing factor (GRF) analog indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA is used to reduce lipodystrophy caused by certain HIV medications. EGRIFTA is not a weight-loss medication and should not be used to treat obesity.

Lipodystrophy Emerging Drugs

* REGN4461: Regeneron Pharmaceuticals

Mibavademab (REGN 4461) is a leptin receptor (LEPR) agonist antibody developed by Regeneron pharmaceuticals to treat generalized lipodystrophy. The drug is currently in Phase II clinical trials conducted on patients with generalized lipodystrophy and familial partial lipodystrophy.

* Subcutaneous Metreleptin: Amryt Pharma

A 12-month randomized, multicenter, double-blind, placebo-controlled Phase III (METRE-PL) study to evaluate the safety and efficacy of daily subcutaneous metreleptin treatment in subjects with partial lipodystrophy.

Get In-Depth Knowledge on Lipodystrophy Market Trends and Forecasts with DelveInsight @ Lipodystrophy Treatment Market [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Lipodystrophy Market Outlook

The market for lipodystrophy treatments is evolving with a focus on both established and emerging therapies. In the United States, the market is dominated by key approved therapies like MYALEPT (metreleptin) and EGRIFTA/EGRIFTA SV (tesamorelin), with substantial revenue contributions from these treatments.

Lipodystrophy Treatment Market Landscape

Lipodystrophy treatment primarily focuses on managing the metabolic complications that result from abnormal fat distribution, such as insulin resistance, diabetes, and hypertriglyceridemia. The approach is personalized based on the type of lipodystrophy and the severity of symptoms. Metabolic management includes medications like metformin for insulin resistance and insulin therapy for diabetes, along with drugs such as fibrates or statins to lower triglyceride levels and reduce cardiovascular risk. Lifestyle modifications involving diet and exercise are also essential for controlling blood sugar levels and maintaining overall health.

Unlock Strategic Insights with DelveInsight's Comprehensive Lipodystrophy Market Report @ Lipodystrophy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/lipodystrophy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Lipodystrophy Market Report

* Coverage- 7MM
* Lipodystrophy Companies- Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
* Lipodystrophy Therapies- Metreleptin, Mibavademab, Baricitinib, and others.
* Lipodystrophy Therapeutic Assessment: Lipodystrophy Current marketed and Lipodystrophy Emerging Therapies
* Lipodystrophy Market Dynamics: Lipodystrophy Market drivers and Lipodystrophy Market Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Lipodystrophy Market Overview at a Glance

4. Methodology

5. Executive Summary

6. Disease Background and Overview

7. Diagnosis

8. Treatment of Lipodystrophy

9. Diagnostic and Treatment Guidelines for Lipodystrophy

10. Conclusion

11. Epidemiology and Patient Population

12. Patient Journey

13. Approved Therapies

14. Emerging Therapies

15. Market Analysis

16. KOL Views

17. Market Barriers

18. Market Drivers

19. SWOT Analysis

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=lipodystrophy-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity



This release was published on openPR.